JP2011526693A - 転移に関連する徴候および決定因子、ならびにそれらの使用方法 - Google Patents
転移に関連する徴候および決定因子、ならびにそれらの使用方法 Download PDFInfo
- Publication number
- JP2011526693A JP2011526693A JP2011516713A JP2011516713A JP2011526693A JP 2011526693 A JP2011526693 A JP 2011526693A JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011526693 A JP2011526693 A JP 2011526693A
- Authority
- JP
- Japan
- Prior art keywords
- determinant
- tumor
- subject
- metastatic
- determinants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 150
- 206010027476 Metastases Diseases 0.000 title claims description 84
- 230000009401 metastasis Effects 0.000 title claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 215
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 164
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 151
- 201000011510 cancer Diseases 0.000 claims abstract description 72
- 239000000090 biomarker Substances 0.000 claims abstract description 51
- 210000004027 cell Anatomy 0.000 claims description 142
- 230000014509 gene expression Effects 0.000 claims description 117
- 238000012360 testing method Methods 0.000 claims description 64
- 238000011282 treatment Methods 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 238000003556 assay Methods 0.000 claims description 36
- 230000008859 change Effects 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 24
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 23
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 23
- 230000025164 anoikis Effects 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- 238000004393 prognosis Methods 0.000 claims description 16
- 238000011269 treatment regimen Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 14
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000001574 biopsy Methods 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 206010061309 Neoplasm progression Diseases 0.000 claims description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000005751 tumor progression Effects 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 238000009098 adjuvant therapy Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 208000037819 metastatic cancer Diseases 0.000 claims description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 4
- 230000008238 biochemical pathway Effects 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 210000002744 extracellular matrix Anatomy 0.000 claims description 4
- 230000000984 immunochemical effect Effects 0.000 claims description 4
- 238000010166 immunofluorescence Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000012292 cell migration Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 abstract description 42
- 102000039446 nucleic acids Human genes 0.000 abstract description 38
- 108020004707 nucleic acids Proteins 0.000 abstract description 38
- 239000002207 metabolite Substances 0.000 abstract description 18
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 8
- 230000004962 physiological condition Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 description 78
- 239000000523 sample Substances 0.000 description 76
- 102100030309 Homeobox protein Hox-A1 Human genes 0.000 description 71
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 description 71
- 201000001441 melanoma Diseases 0.000 description 61
- 230000009545 invasion Effects 0.000 description 49
- 238000004458 analytical method Methods 0.000 description 43
- 238000005259 measurement Methods 0.000 description 34
- 210000002752 melanocyte Anatomy 0.000 description 32
- 239000013598 vector Substances 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 210000004072 lung Anatomy 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 238000004422 calculation algorithm Methods 0.000 description 20
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 19
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 19
- 238000012216 screening Methods 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 17
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 15
- 241000699660 Mus musculus Species 0.000 description 15
- 208000021039 metastatic melanoma Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000003462 vein Anatomy 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 13
- 239000012491 analyte Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 108010082117 matrigel Proteins 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 230000008595 infiltration Effects 0.000 description 11
- 238000001764 infiltration Methods 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000010877 transwell invasion assay Methods 0.000 description 11
- 102000009300 Fascin-1 Human genes 0.000 description 10
- 108050000138 Fascin-1 Proteins 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000002596 correlated effect Effects 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 206010056342 Pulmonary mass Diseases 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 description 8
- 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000010195 expression analysis Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000013074 reference sample Substances 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 230000004709 cell invasion Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 208000030381 cutaneous melanoma Diseases 0.000 description 7
- 238000010448 genetic screening Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 201000003708 skin melanoma Diseases 0.000 description 7
- 238000012706 support-vector machine Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 6
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102100029974 GTPase HRas Human genes 0.000 description 6
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 6
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000007635 classification algorithm Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 229960003722 doxycycline Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102100032951 Condensin complex subunit 2 Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000942617 Homo sapiens Condensin complex subunit 2 Proteins 0.000 description 5
- 102000002278 Ribosomal Proteins Human genes 0.000 description 5
- 108010000605 Ribosomal Proteins Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 230000005014 ectopic expression Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003068 pathway analysis Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102000004064 Geminin Human genes 0.000 description 4
- 108090000577 Geminin Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 101100517384 Mus musculus Ntrk2 gene Proteins 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000008236 biological pathway Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 230000005748 tumor development Effects 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102100027447 ATP-dependent DNA helicase Q1 Human genes 0.000 description 3
- 240000005020 Acaciella glauca Species 0.000 description 3
- 108700020472 CDC20 Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 101150023302 Cdc20 gene Proteins 0.000 description 3
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102100040795 DNA primase large subunit Human genes 0.000 description 3
- 102100033711 DNA replication licensing factor MCM7 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 3
- 102100023999 Heterogeneous nuclear ribonucleoprotein R Human genes 0.000 description 3
- 101000580659 Homo sapiens ATP-dependent DNA helicase Q1 Proteins 0.000 description 3
- 101000611553 Homo sapiens DNA primase large subunit Proteins 0.000 description 3
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 3
- 101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 3
- 101001047853 Homo sapiens Heterogeneous nuclear ribonucleoprotein R Proteins 0.000 description 3
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 description 3
- 101000920618 Homo sapiens Transcription and mRNA export factor ENY2 Proteins 0.000 description 3
- 101000763472 Homo sapiens Transmembrane protein 141 Proteins 0.000 description 3
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 208000007256 Nevus Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 3
- 102100031954 Transcription and mRNA export factor ENY2 Human genes 0.000 description 3
- 102100027029 Transmembrane protein 141 Human genes 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 201000008274 breast adenocarcinoma Diseases 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 235000003499 redwood Nutrition 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000012130 whole-cell lysate Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102100033393 Anillin Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 238000007808 Cell invasion assay Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000732632 Homo sapiens Anillin Proteins 0.000 description 2
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 2
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 2
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 208000032452 Nevus, Epithelioid and Spindle Cell Diseases 0.000 description 2
- 101150056950 Ntrk2 gene Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000002358 circulating endothelial cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 201000010078 malignant spindle cell melanoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003101 melanogenic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 101150087123 nat gene Proteins 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000019798 spindle cell melanoma Diseases 0.000 description 2
- 208000011584 spitz nevus Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100022313 2-iminobutanoate/2-iminopropanoate deaminase Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 102100035366 Centromere protein M Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108090000288 Glycoproteins Chemical group 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- -1 HRSPI2 Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000681020 Homo sapiens 2-iminobutanoate/2-iminopropanoate deaminase Proteins 0.000 description 1
- 101000737696 Homo sapiens Centromere protein M Proteins 0.000 description 1
- 101000898310 Homo sapiens Enhancer of filamentation 1 Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000618133 Homo sapiens Sperm-associated antigen 5 Proteins 0.000 description 1
- 101000620880 Homo sapiens Tartrate-resistant acid phosphatase type 5 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000087799 Koma Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101150033052 MAS5 gene Proteins 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100348089 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BUR6 gene Proteins 0.000 description 1
- 101100344462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YDJ1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100021915 Sperm-associated antigen 5 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000245032 Trillium Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 238000013476 bayesian approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012117 colonization screening Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 1
- 230000008600 mitotic progression Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000177 oncogenetic effect Effects 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000009 pyrolysis mass spectrometry Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000005514 radiochemical analysis Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 230000024122 regulation of cell motility Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 102200055464 rs113488022 Human genes 0.000 description 1
- 102200127349 rs11547328 Human genes 0.000 description 1
- 102200029029 rs149082963 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000019130 spindle checkpoint Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7593308P | 2008-06-26 | 2008-06-26 | |
| US61/075,933 | 2008-06-26 | ||
| PCT/US2009/048862 WO2009158620A2 (en) | 2008-06-26 | 2009-06-26 | Signatures and determinants associated with metastasis methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526693A true JP2011526693A (ja) | 2011-10-13 |
| JP2011526693A5 JP2011526693A5 (enExample) | 2012-05-31 |
Family
ID=41445345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516713A Withdrawn JP2011526693A (ja) | 2008-06-26 | 2009-06-26 | 転移に関連する徴候および決定因子、ならびにそれらの使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110182881A1 (enExample) |
| EP (1) | EP2307886A2 (enExample) |
| JP (1) | JP2011526693A (enExample) |
| KR (1) | KR20110036056A (enExample) |
| CN (1) | CN102132160A (enExample) |
| AU (1) | AU2009262022A1 (enExample) |
| BR (1) | BRPI0914734A2 (enExample) |
| CA (1) | CA2728674A1 (enExample) |
| IL (1) | IL210245A0 (enExample) |
| MX (1) | MX2010014280A (enExample) |
| NZ (1) | NZ590385A (enExample) |
| RU (1) | RU2011102743A (enExample) |
| WO (1) | WO2009158620A2 (enExample) |
| ZA (1) | ZA201100225B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US20100248269A1 (en) * | 2009-03-30 | 2010-09-30 | New York Blood Center | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer |
| AU2011216404B2 (en) | 2010-02-17 | 2016-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2013533960A (ja) | 2010-06-01 | 2013-08-29 | トドス メディカル リミテッド | がんの診断 |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2012030840A2 (en) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| US8880457B2 (en) * | 2010-11-05 | 2014-11-04 | Allegheny-Singer Research Institute | Method and system for recommending a decision based on combined entity modeling |
| US9719937B2 (en) | 2011-05-11 | 2017-08-01 | Todos Medical Ltd. | Diagnosis of cancer |
| US20140302042A1 (en) * | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| CN103842813B (zh) * | 2011-09-06 | 2018-04-17 | 贝克顿·迪金森公司 | 用于对样品中的稀少目标细胞进行细胞计数检测的方法和组合物 |
| WO2014036470A1 (en) | 2012-08-31 | 2014-03-06 | Sloan-Kettering Institute For Cancer Research | Particles, methods and uses thereof |
| JP6164678B2 (ja) * | 2012-10-23 | 2017-07-19 | 国立研究開発法人科学技術振興機構 | ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム |
| WO2014078700A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| JP6465811B2 (ja) | 2012-12-19 | 2019-02-06 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 多様式の粒子、方法およびその使用 |
| AU2014218867B2 (en) | 2013-02-20 | 2018-11-08 | Sloan-Kettering Institute For Cancer Research | Wide field raman imaging apparatus and associated methods |
| EP4265740A3 (en) * | 2013-03-14 | 2024-04-24 | Castle Biosciences, Inc. | Methods for predicting risk of metastasis in cutaneous melanoma |
| EP3004870B1 (en) | 2013-05-28 | 2019-01-02 | Todos Medical Ltd. | Differential diagnosis of benign tumors |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US10912947B2 (en) | 2014-03-04 | 2021-02-09 | Memorial Sloan Kettering Cancer Center | Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells |
| US20150252434A1 (en) * | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2016018896A1 (en) | 2014-07-28 | 2016-02-04 | Memorial Sloan Kettering Cancer Center | Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes |
| US11009467B2 (en) * | 2015-02-17 | 2021-05-18 | Siemens Healthcare Diagnostics Inc. | Model-based methods and apparatus for classifying an interferent in specimens |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| WO2017004301A1 (en) | 2015-07-01 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Anisotropic particles, methods and uses thereof |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| CN109844140A (zh) * | 2016-10-28 | 2019-06-04 | 茂英基因科技股份有限公司 | 辨识转移性肿瘤的原发位置的方法及系统 |
| US20200224277A1 (en) * | 2017-07-17 | 2020-07-16 | Mao Ying Genetech Inc. | Cell type identification method and system thereof |
| CN109932510B (zh) * | 2017-12-18 | 2022-07-12 | 天津云检医学检验所有限公司 | 一种宫颈癌生物标志物及其检测试剂盒 |
| JP7580210B2 (ja) * | 2020-06-15 | 2024-11-11 | 三菱重工業株式会社 | 予兆判定装置、予兆判定方法及びプログラム |
| CA3233047A1 (en) * | 2021-09-20 | 2023-03-23 | Droplet Biosciences, Inc. | Methods for disease assessment using drain fluid |
| AU2022405276A1 (en) * | 2021-12-08 | 2024-07-11 | Mayo Foundation For Medical Education And Research | Assessing and treating melanoma |
| CN116204890B (zh) * | 2023-04-28 | 2023-07-21 | 浙江鹏信信息科技股份有限公司 | 一种自适应增强人工智能算法安全的算法组件库 |
| CN117171678B (zh) * | 2023-11-02 | 2024-01-12 | 北京建工环境修复股份有限公司 | 一种微生物修复过程中土壤微生物菌群调控方法及系统 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1178414A (en) * | 1978-02-08 | 1984-11-27 | Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) | Packaging material having excellent seal packaging property |
| US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| US4727022A (en) * | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
| US5018067A (en) * | 1987-01-12 | 1991-05-21 | Iameter Incorporated | Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US20020038227A1 (en) * | 2000-02-25 | 2002-03-28 | Fey Christopher T. | Method for centralized health data management |
| WO2003025141A2 (en) * | 2001-09-19 | 2003-03-27 | Intergenetics Incorporated | Genetic analysis for stratification of cancer risk |
| US20040122296A1 (en) * | 2002-12-18 | 2004-06-24 | John Hatlestad | Advanced patient management for triaging health-related data |
| US7468032B2 (en) * | 2002-12-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Advanced patient management for identifying, displaying and assisting with correlating health-related data |
| US20030232398A1 (en) * | 2002-03-28 | 2003-12-18 | Macmurray James P. | Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer |
| US20050208500A1 (en) * | 2003-03-04 | 2005-09-22 | Erlander Mark G | Signatures of ER status in breast cancer |
| EP1751306A1 (en) * | 2004-04-30 | 2007-02-14 | Yale University | Methods and compositions for cancer diagnosis |
| JP5184087B2 (ja) * | 2004-09-22 | 2013-04-17 | トリパス イメージング， インコーポレイテッド | ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品 |
| WO2007059313A1 (en) * | 2005-11-16 | 2007-05-24 | Children's Medical Center Corporation | Method to assess breast cancer risk |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US20090069196A1 (en) * | 2006-03-22 | 2009-03-12 | Mathias Gehrmann | Prediction of Breast Cancer Response to Chemotherapy |
| NZ575090A (en) * | 2006-09-06 | 2012-02-24 | Univ California | Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers |
| RU2009114745A (ru) * | 2006-09-19 | 2010-10-27 | Новартис АГ (CH) | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования |
| EP2092075A2 (en) * | 2006-11-06 | 2009-08-26 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of melanoma |
| EP2155897A2 (en) * | 2007-03-30 | 2010-02-24 | Source Precision Medicine, Inc. d/b/a Source MDX. | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| US20110160072A1 (en) * | 2007-10-23 | 2011-06-30 | Clinical Genomics Pty. Ltd. | Method of diagnosing neoplasms |
| NZ587903A (en) * | 2008-02-14 | 2013-05-31 | Decode Genetics Ehf | Susceptibility for lung cancer using the polymorphic marker rs1051730 |
| WO2009124251A1 (en) * | 2008-04-03 | 2009-10-08 | Sloan-Kettering Institute For Cancer Research | Gene signatures for the prognosis of cancer |
| CA2724348A1 (en) * | 2008-05-15 | 2009-11-19 | University Of Southern California | Genotype and expression analysis for use in predicting outcome and therapy selection |
| WO2011063274A2 (en) * | 2009-11-23 | 2011-05-26 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
-
2009
- 2009-06-26 RU RU2011102743/15A patent/RU2011102743A/ru not_active Application Discontinuation
- 2009-06-26 MX MX2010014280A patent/MX2010014280A/es not_active Application Discontinuation
- 2009-06-26 KR KR1020117001619A patent/KR20110036056A/ko not_active Withdrawn
- 2009-06-26 JP JP2011516713A patent/JP2011526693A/ja not_active Withdrawn
- 2009-06-26 WO PCT/US2009/048862 patent/WO2009158620A2/en not_active Ceased
- 2009-06-26 EP EP09771151A patent/EP2307886A2/en not_active Withdrawn
- 2009-06-26 CN CN2009801331437A patent/CN102132160A/zh active Pending
- 2009-06-26 BR BRPI0914734A patent/BRPI0914734A2/pt not_active IP Right Cessation
- 2009-06-26 AU AU2009262022A patent/AU2009262022A1/en not_active Abandoned
- 2009-06-26 CA CA2728674A patent/CA2728674A1/en not_active Abandoned
- 2009-06-26 NZ NZ590385A patent/NZ590385A/xx not_active IP Right Cessation
- 2009-06-26 US US13/001,203 patent/US20110182881A1/en not_active Abandoned
-
2010
- 2010-12-23 IL IL210245A patent/IL210245A0/en unknown
-
2011
- 2011-01-07 ZA ZA2011/00225A patent/ZA201100225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2307886A2 (en) | 2011-04-13 |
| MX2010014280A (es) | 2011-05-23 |
| KR20110036056A (ko) | 2011-04-06 |
| RU2011102743A (ru) | 2012-08-10 |
| WO2009158620A2 (en) | 2009-12-30 |
| CA2728674A1 (en) | 2009-12-30 |
| BRPI0914734A2 (pt) | 2015-10-20 |
| IL210245A0 (en) | 2011-03-31 |
| ZA201100225B (en) | 2011-10-26 |
| US20110182881A1 (en) | 2011-07-28 |
| WO2009158620A3 (en) | 2010-06-03 |
| NZ590385A (en) | 2012-11-30 |
| AU2009262022A1 (en) | 2009-12-30 |
| CN102132160A (zh) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526693A (ja) | 転移に関連する徴候および決定因子、ならびにそれらの使用方法 | |
| Dinh et al. | Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube | |
| Chen et al. | Gene expression patterns in human liver cancers | |
| AU2021212151B2 (en) | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm | |
| JP2011528442A (ja) | 前立腺癌に関連した兆候およびｐｃｄｅｔｅｒｍｉｎａｎｔ、ならびにそれらの使用方法 | |
| US20140302042A1 (en) | Methods of predicting prognosis in cancer | |
| WO2013003384A1 (en) | Signatures and determinants associated with prostate cancer progression and methods of use thereof | |
| JP2019537108A (ja) | 癌の分類および予後 | |
| JP2015500010A (ja) | 結腸直腸癌の予後のための方法およびキット | |
| KR20230011905A (ko) | 파노믹 게놈 유병률 점수 | |
| WO2015073949A1 (en) | Method of subtyping high-grade bladder cancer and uses thereof | |
| CA3096529A1 (en) | Improved classification and prognosis of prostate cancer | |
| US20130143753A1 (en) | Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom | |
| Chen et al. | The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma | |
| Guel et al. | Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancer | |
| EP2721178B1 (en) | Method for the prognosis of breast cancer based on expression markers | |
| KR20210016362A (ko) | 결장암 예측 바이오마커로서의 l1td1 | |
| US9606122B2 (en) | Prognosis of oesophageal and gastro-oesophageal junctional cancer | |
| Caputo et al. | Alterations in the preneoplastic breast microenvironment of BRCA1/2 mutation carriers revealed by spatial transcriptomics | |
| WO2022082317A1 (en) | Gene signature for predicting progression and progress of urinary cancers and methods of use thereof | |
| KR20240126130A (ko) | 대장암 예후 예측용 바이오마커, 및 이를 이용한 예후 예측 방법 | |
| Young | A translational study in pancreatic neuroendocrine neoplasms | |
| CN117568482A (zh) | 用于胃癌预后的分子标记物及其应用 | |
| CN118661103A (zh) | 雌激素受体(er)阳性样和雌激素受体(er)阴性样乳腺癌的蛋白质标志物 | |
| Class et al. | Patent application title: METHOD FOR THE PROGNOSIS OF BREAST CANCER BASED ON THE EXPRESSION OF THE GENE PIN1 IN COMBINATION WITH MUTATIONS IN THE GENE TP53 Inventors: Giannino Del Sal (Trieste, IT) Marco Napoli (Palermo, IT) Javier Girardini Brovelli (Rosario, AR) Silvano Piazza (Latisana, IT) Alastair Thompson (Auchterarder, GB) Assignees: University of Dundee Universita Degli Studi di Trieste |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120330 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130808 |